Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Form 483
Pharma
China biotech deals, Takeda, LaNova—Fierce Pharma Asia
Biotech deals originating out of China are surging. Takeda touts a pair of OX2R phase 3 wins. Merck's PD-1xVEGF partner is being acquired. And more.
Angus Liu
Jul 18, 2025 9:04am
Trump's tariffs, Leqembi, Kyowa Kirin—Fierce Pharma Asia
Apr 18, 2025 9:25am
Aurobindo discloses FDA Form 483 at North Carolina inhaler plant
Apr 14, 2025 3:00pm
Eisai, ex-NMPA official, Pfizer-Summit—Fierce Pharma Asia
Feb 28, 2025 8:45am
FDA hits Piramal with 6-observation Form 483 at India API plant
Feb 26, 2025 10:22am
FDA scrutinizes Novo on production issues at semaglutide plant
Oct 31, 2024 9:33am
